Skip to main content
SpringerLink
Log in

Langersehnter Erfolg — Entzündungshemmer verhindert Herzinfarkte

  • Medizin aktuell
  • Published:
CardioVasc Aims and scope

Erstmals ist es gelungen, mit einem antientzündlichen Therapieansatz die Prognose von herzkranken Patienten zu verbessern. In der CANTOS-Studie reduzierte der Antikörper Canakinumab das relative Risiko für kardiovaskuläre Komplikationen um 15 %.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Quelle

  • Ridker PM et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017; https://doi.org/10.1056/NEJMoa1707914

  • Harrington RA. Targeting Inflammation in Coronary Artery Disease. N Engl J Med. 2017; https://doi.org/10.1056/NEJMoa1709904

Download references

Author information

Authors and Affiliations

  1. http://www.springermedizin.de

    Dirk Einecke

Authors
  1. Dirk Einecke
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Einecke, D. Langersehnter Erfolg — Entzündungshemmer verhindert Herzinfarkte. CV 17, 10–11 (2017). https://doi.org/10.1007/s15027-017-1163-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15027-017-1163-4

Search

Navigation